GlaxoSmithKline expanded a collaboration with NPS Pharmaceuticals to take over development and marketing of ronacaleret. The drug was designed to treat osteoporosis, but GSK will develop it as stem cell transplant therapy. The agreement also grants
NPS development rights to SB-423557 and SB-423562 for autosomal dominant hypocalcemia with hypercalciuria.

Full Story:

Related Summaries